RARE Daily

Chiesi Wins Canadian Approval of Ferriprox Extended-Release Tablets to Treat Transfusional Iron Overload

April 3, 2023

Rare Daily Staff

Health Cananda has approved Chiesi Global Rare Diseases Ferriprox MR extended-release tablets for the treatment of patients with transfusional iron overload due to thalassemia syndromes, sickle cell disease. or other anemias.

Thalassemia syndromes and sickle cell disease (SCD) are disorders that affect red blood cells. Both conditions cause problems with hemoglobin, depriving many parts of the body of oxygen. People living with these conditions often require chronic blood transfusions that can put them at risk of developing very high levels of iron in their blood and vital organs. Ferriprox is a synthetic, orally active iron-chelating agent shown to be effective in reducing iron concentration by penetrating cell membranes and removing toxic iron from organ tissues and extracellular fluids.

Ferriprox is a synthetic, orally active iron-chelating agent shown to be effective in reducing iron concentration by penetrating cell membranes and removing toxic iron from organ tissues and extracellular fluids.

Ferriprox was previously approved in Canada for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate in 2015, and subsequently approved for the treatment of iron overload in patients with SCD or other anemias in 2021. Ferriprox is also FDA approved for the treatment of transfusional iron overload due to thalassemia syndromes, including beta-thalassemia, when current chelation therapy is inadequate.

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube